Repligen
RGEN
Repligen (RGEN) - Total assets
Total assets on the balance sheet as of March 2024 : $2.84 B
According to Repligen 's latest financial reports the company's total assets are $2.84 B. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Repligen - Total assets on balance sheet (from 2001 to 2024)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2023-12-31 | $2.82 B | 11.87% |
| 2022-12-31 | $2.52 B | 7.05% |
| 2021-12-31 | $2.35 B | 23.94% |
| 2020-12-31 | $1.90 B | 35.91% |
| 2019-12-31 | $1.40 B | 80.75% |
| 2018-12-31 | $0.77 B | 4.18% |
| 2017-12-31 | $0.74 B | 157.35% |
| 2016-12-31 | $0.28 B | 97.56% |
| 2015-12-31 | $0.14 B | 13.99% |
| 2014-12-31 | $0.12 B | 8.13% |
| 2013-12-31 | $0.11 B | 22.3% |
| 2012-12-31 | $97.01 M | |
| 2011-03-31 | $72.29 M | 1.22% |
| 2010-03-31 | $71.41 M | -3.17% |
| 2009-03-31 | $73.75 M | 7.14% |
| 2008-03-31 | $68.83 M | 136.76% |
| 2007-03-31 | $29.07 M | 1.67% |
| 2006-03-31 | $28.59 M | 3.59% |
| 2005-03-31 | $27.6 M | -6.78% |
| 2004-03-31 | $29.61 M | 10.53% |
| 2003-03-31 | $26.79 M | -7.96% |
| 2002-03-31 | $29.11 M | -9.45% |
| 2001-03-31 | $32.14 M |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $226.50 B | 7,849.44% | 🇺🇸 USA |
 Thermo Fisher Scientific TMO | $98.72 B | 3,364.96% | 🇺🇸 USA |
 General Electric GE | $163.94 B | 5,653.82% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $99.03 B | 3,375.66% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | $0.16 B | -94.20% | 🇺🇸 USA |
 Novavax NVAX | $1.79 B | -36.91% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | $3.47 B | 21.87% | 🇺🇸 USA |
 Bio-Techne TECH | $2.73 B | -4.16% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | $6.87 B | 141.21% | 🇺🇸 USA |
 Charles River Laboratories
CRL | $8.19 B | 187.62% | 🇺🇸 USA |